18556461. GLUCAGON LIKE PEPTIDE COMPOUNDS simplified abstract (Novartis AG)

GLUCAGON LIKE PEPTIDE COMPOUNDS

Organization Name

Novartis AG

Inventor(s)

Valerie Beaulieu of North Reading MA (US)

Keith Galyan of Lake Villa IL (US)

Jinhai Gao of Belmont MA (US)

Carol Ginsburg-moraff of Cambridge MA (US)

Pankaj Jain of Belmont MA (US)

Jovita Marcinkeviciene of Lexington MA (US)

Walter Michael of Watertown MA (US)

Muneto Mogi of Waltham MA (US)

Martin Marro of Newton MA (US)

Sejal Patel of Lexington MA (US)

Scott Plummer of Somerville MA (US)

Alok Singh of Sudbury MA (US)

Aimee Usera of Winchester MA (US)

GLUCAGON LIKE PEPTIDE COMPOUNDS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18556461 titled 'GLUCAGON LIKE PEPTIDE COMPOUNDS

Simplified Explanation: The patent application describes novel compounds that combine a GLP-1 compound with a fatty acid or its derivative.

• These compounds are manufactured and used for their potential benefits in various applications.
• The innovation lies in the unique combination of GLP-1 and fatty acids, offering new possibilities in the field.
• The compounds may have implications in the treatment of certain conditions or diseases.
• By addressing specific problems related to GLP-1 and fatty acids, these compounds offer a novel approach to therapy.
• The benefits of these compounds may include improved efficacy and reduced side effects compared to existing treatments.

Potential Applications: The technology could be applied in the pharmaceutical industry for the development of new therapies targeting metabolic disorders or other conditions.

Problems Solved: The technology addresses challenges related to the effectiveness and side effects of existing GLP-1-based treatments.

Benefits: The technology offers the potential for enhanced therapeutic outcomes and improved patient experiences.

Commercial Applications: The technology could have commercial applications in the development of novel pharmaceutical products for metabolic disorders, potentially impacting the market for related treatments.

Questions about GLP-1 and Fatty Acid Compounds: 1. What are the potential therapeutic applications of combining GLP-1 compounds with fatty acids? 2. How do these novel compounds compare to existing treatments in terms of efficacy and side effects?

Original Abstract Submitted

Provided herein are novel compounds comprising a GLP-1 compound and a fatty acid or fatty acid derivative, the manufacture of said novel compounds and the use thereof.